David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Alok A. Khorana, MD, on Preventing Venous Thromboembolism

Alok A. Khorana, MD, of the Cleveland Clinic, discusses study results on the use of dalteparin for thromboprophylaxis in cancer patients at high risk for the condition (Abstract 427).

Leukemia

Hagop M. Kantarjian, MD

Hagop M. Kantarjian, MD, on AML: Safety and Efficacy of Guadecitabine

Hagop M. Kantarjian, MD, of MD Anderson Cancer Center, discusses a study that compared efficacy and safety results of using 5-day and 10-day regimens of a novel hypomethylating agent in 103 treatment-naïve AML patients who were not candidates for intensive chemotherapy (Abstract 458).

Lymphoma

Laurie H. Sehn, MD, MPH

Laurie H. Sehn, MD, MPH, on Classical HL: New Findings on the Need for Radiotherapy

Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a study that showed patients with advanced-stage classical Hodgkin lymphoma, with a negative PET-scan following ABVD chemotherapy, have excellent outcomes without the need for consolidative radiotherapy, regardless of disease bulk at presentation (Abstract 579).

Leukemia

Lymphoma

Sagar Lonial, MD, and Alessandra Tedeschi, MD

Sagar Lonial, MD, and Alessandra Tedeschi, MD, on CLL/SLL: Results From the RESONATE-2 Trial

Sagar Lonial, MD, of the Emory University School of Medicine, and Alessandra Tedeschi, MD, of the Azienda Ospedaliera Niguarda Cà Granda, discuss this international study of ibrutinib vs chlorambucil in patients 65 years and older with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma (Abstract 495).

Leukemia

James Foran, MD

James Foran, MD, on Clofarabine for AML: Clinical Trial Results of ECOG-ACRIN and ALFA/Clara

James Foran, MD, of the Mayo Clinic Cancer Center, discusses two key studies on clofarabine: as a single agent for induction and postremission therapy in newly diagnosed AML, and as the basis for consolidation in nonfavorable AML (Abstracts 217 and 218).

Aug

Today In Oncology

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

Alok A. Khorana, MD, on Preventing Venous Thromboembolism

Hagop M. Kantarjian, MD, on AML: Safety and Efficacy of Guadecitabine

Laurie H. Sehn, MD, MPH, on Classical HL: New Findings on the Need for Radiotherapy

Sagar Lonial, MD, and Alessandra Tedeschi, MD, on CLL/SLL: Results From the RESONATE-2 Trial

James Foran, MD, on Clofarabine for AML: Clinical Trial Results of ECOG-ACRIN and ALFA/Clara

Dr. Gary R. Morrow, a Pioneer in Cancer Research, Dies at 82

Research Finds Supercentenarians Have an Abundance of CD4 CTLs

ASCO Remembers Supportive Care and Symptom Management Pioneer Gary R. Morrow, PhD, MS

FDA Approves Zanidatamab Combination Regimens for HER2 Gastric GEJ or Esophageal Cancer

Metabolic Syndrome Frequently Documented During First Year of ADT-ARPI Therapy in Prostate Cancer